Raphael Pharmaceutical Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
RAPHStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Statements of Cash Flows
| Three months ended March 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash flows from operating activities | ||||
| Net loss | $(429) | $(550) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | (* | ) | (* | ) |
| Stock based compensation | 197 | - | ||
| Changes in: | ||||
| Other current assets | (35) | (6) | ||
| Account payables and related party | 58 | 384 | ||
| Net cash used in operating activities | (209) | (172) | ||
| Cash flows from investing activities | ||||
| Purchase of fixed assets | - | (1) | ||
| Net cash used in investing activities | - | (1) | ||
| Cash flows from financing activities | ||||
| Issuance of common stock and warrants** | 240 | 180 | ||
| Receipt for warrants exercise | - | 50 | ||
| Net cash provided by financing activities | 240 | 230 | ||
| Change in cash and cash equivalents | 31 | 57 | ||
| Cash and cash equivalents at the beginning of the period | 19 | 230 | ||
| Cash and cash equivalents at the end of the period | $50 | $287 | ||
| (*) | less than $1 thousand |
|---|
| ** | In March 2025,a company's director was granted 350,000 shares and 250,000 options in exchange for his services. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.